Presentations and Postersby Voluntary Organization JBCRG
2006
The effect of pathological response of multicenter phase II trial of fluorouracil, epirubicin, cyclophosphamide (FEC 100) followed by docetaxel (DOC 75) in primary operable breast cancer.
Nakamura S, Toi M, Takatsuka Y, Kuroi K, Iwata H, Ohno S, Masuda N, Tsuda H, Kurosumi M, Akiyama F; Japan Breast Cancer Research Group (JBCRG)
5th European Breast Cancer Conference, Nice (France), Mar. 2006
Premature ovarian disfunction induced by neopadjuvantr chemotherapy (FEC followed by docetaxel) for breast cancer
Shinano Hitomi, Hamaoka Tsuyoshi, Nakamura Seigo, Toi Masakazu, Kuroi Katsumasa; Japan Breast Cancer Research Group (JBCRG).
3rd Organisation for Oncology and Translational Research, Hong Kong, Oral, Sep. 2006
Significance of HER2 for predicting pathological complete response to preoperative treatment with FEC followed by docetaxel
Toi M, Nakamura S, Takatsuka Y, Kuroi K, Iwata H, Ohno S, Masuda N, Tsuda H, Kurosumi M, Akiyama F；Japan Breast Cancer Research Group (JBCRG).
29th San Antonio Breast Cancer Symposium, Poster, San Antonio (USA), Dec. 2006